Alzheimer’s Drug Shows Promise
MAYO ANNOUNCES POSITIVE CLINICAL TRIAL
An experimental Alzheimer’s drug called Lecanemab has shown encouraging results, according to researchers. The drug slowed cognitive and functional decline in the early stages of the disease, causing guarded optimism among scientists in the wake of numerous Alzheimer’s drug trials that have failed. According to the director of the Mayo Clinic in Minnesota, Ronald Petersen, Lecanemab slowed the disease by 27% compared with a placebo, offering hope for those diagnosed and their loved ones. Researchers have been focused on slowing the advance of Alzheimer’s for decades, and the number of Americans living with the disease is expected to double to 13 million by 2050, according to the Alzheimer’s Association. Data from the 1,800-patient trial confirmed what researchers have suspected for years: that removal of deposits of a sticky protein called amyloid from the brains of patients with early Alzheimer’s can delay progression of the disease. Unlike other drugs that have focused on amyloid, Lecanemab targets pockets of the plaque that have not yet clumped together. Eisai – Biogen, makers of the drug, are currently seeking approval from the FDA.